CDN1163
SERCA activator / Allosteric activator of the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA).1,2 It lowered fasting glucose levels, improved glucose tolerance, and ameliorated hepatitis steatosis in ob/ob mice.1 CDN1163 also rescued neurons from ER-stress-induced cell death in vitro and displayed significant efficacy in a rat 6-hydroxydopamine (6-OHDA) model of Parkinson’s disease.2 It reduced age-related muscle atrophy and weakness in a C57BL/6J mice.3 CDN1163 decreased inflammatory cytokines and chemokines and attenuated mitochondrial dysfunction in Influenza A infected H1395 cells.4
Biochemicals & reagents
892711-75-0
Kang et al. (2016), Small Molecular Allosteric Activator of the Sarco/Endoplasmic Reticulum Ca2+-ATPase (SERCA) Attenuates Diabetes and Metabolic Disorders; J. Biol. 291 5185 Dahl (2017), A new target for Parkinson’s disease: Small molecule SERCA activator CDN1163 ameliorates dyskinesia in 6-OHDA-lesioned rats; Bioorg. Med. Chem. 25 53 Qaisar et al. (2020), Restoration of Sarcoplasmic Reticulum Ca2+ ATPase (SERCA) Activity Prevents Age-Related Muscle Atrophy and Weakness in Mice; Int. J. Mol. Sci. 22 37 Peng et al. (2021), Sarco/Endoplasmic Reticulum Ca2+ Transporting ATPase (SERCA) Modulates Autophagic, Inflammatory, and Mitochondrial Responses during Influenza A Virus Infection in Human Lung Cells; J. Virol. 1128/JVI00217-21
-20°C
TARGET: ATPase; ER/Golgi; UPR (Unfolded protein response) -- PATHWAY: Glucose metabolism; Mitochondrial function; Calcium signaling; Cholesterol metabolism -- RESEARCH AREA: Cellular stress; Oxidative stress; Neuroscience -- DISEASE AREA: Liver disease; NeurodegenerationInflammation; Diabetes